KR20190043609A - 프로인슐린 유도체 - Google Patents

프로인슐린 유도체 Download PDF

Info

Publication number
KR20190043609A
KR20190043609A KR1020197009616A KR20197009616A KR20190043609A KR 20190043609 A KR20190043609 A KR 20190043609A KR 1020197009616 A KR1020197009616 A KR 1020197009616A KR 20197009616 A KR20197009616 A KR 20197009616A KR 20190043609 A KR20190043609 A KR 20190043609A
Authority
KR
South Korea
Prior art keywords
amino acid
insulin
peptide
arg
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197009616A
Other languages
English (en)
Korean (ko)
Inventor
디미트리오스 가토스
알렉산드라 아나스타시우
클레오메니스 바를로스
Original Assignee
케미컬 앤드 바이오파마슈티컬 라보라토리즈 오브 파트라스 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 케미컬 앤드 바이오파마슈티컬 라보라토리즈 오브 파트라스 에스.에이. filed Critical 케미컬 앤드 바이오파마슈티컬 라보라토리즈 오브 파트라스 에스.에이.
Publication of KR20190043609A publication Critical patent/KR20190043609A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
KR1020197009616A 2016-09-06 2017-09-05 프로인슐린 유도체 Ceased KR20190043609A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GR20160100458 2016-09-06
GR20160100458 2016-09-06
PCT/IB2017/055336 WO2018047062A1 (en) 2016-09-06 2017-09-05 Proinsulin derivatives

Publications (1)

Publication Number Publication Date
KR20190043609A true KR20190043609A (ko) 2019-04-26

Family

ID=59895344

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197009616A Ceased KR20190043609A (ko) 2016-09-06 2017-09-05 프로인슐린 유도체

Country Status (10)

Country Link
US (1) US11230585B2 (https=)
EP (1) EP3509625A1 (https=)
JP (1) JP2019530473A (https=)
KR (1) KR20190043609A (https=)
CN (1) CN110234339A (https=)
AU (1) AU2017322552B2 (https=)
BR (1) BR112019004314A2 (https=)
CA (1) CA3035850A1 (https=)
IL (1) IL265182A (https=)
WO (1) WO2018047062A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3756679A1 (en) 2019-06-28 2020-12-30 Université de Genève Compositions for use in the treatment of insulin deficiency conditions

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK58285D0 (da) 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
DK129385A (da) 1985-03-22 1986-09-23 Novo Industri As Peptider og fremstilling deraf
DK10191D0 (da) 1991-01-22 1991-01-22 Novo Nordisk As Hidtil ukendte peptider
US5304473A (en) * 1991-06-11 1994-04-19 Eli Lilly And Company A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
WO1995016708A1 (en) 1993-12-17 1995-06-22 Novo Nordisk A/S Proinsulin-like compounds
BR9408638A (pt) 1994-12-29 2004-09-21 Bio Technology General Corp Geração de insulina humana
CN1231259C (zh) * 1994-12-29 2005-12-14 萨文特医药公司 生产人胰岛素
EP0741188A3 (en) 1995-05-05 1999-07-14 Eli Lilly And Company Single chain insulin with high bioactivity
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
JP2001521006A (ja) 1997-10-24 2001-11-06 イーライ・リリー・アンド・カンパニー 不溶性インシュリン組成物
GB9812675D0 (en) 1998-06-11 1998-08-12 Univ Edinburgh Peptides
EP1193272B1 (en) 2000-10-02 2004-06-30 Yonsei University Single-chain insulin analogs
KR100449454B1 (ko) * 2000-10-02 2004-09-21 이현철 단일사슬 인슐린 유도체의 유전자를 포함하는 당뇨병치료용 벡터
WO2002079251A2 (en) * 2001-04-02 2002-10-10 Novo Nordisk A/S Method for making human insulin precursors
EP1692168B1 (en) 2003-12-03 2011-07-20 Novo Nordisk A/S Single-chain insulin
JP2008533100A (ja) 2005-03-18 2008-08-21 ノボ ノルディスク アクティーゼルスカブ Ｐｅｇ化された単鎖インスリン
US20090069216A1 (en) 2006-02-21 2009-03-12 Novo Nordisk A/S Single-Chain Insulin Analogues and Pharmaceutical Formulations Thereof
JP2009530243A (ja) 2006-03-13 2009-08-27 ノボ・ノルデイスク・エー／エス アシル化単鎖インスリン
WO2008043033A2 (en) 2006-10-04 2008-04-10 Case Western Reserve University Fibrillation-resistant insulin and insulin analogues
US10100098B2 (en) * 2006-12-13 2018-10-16 Stelis Biopharma Private Limited Insulin production methods and proinsulin constructs
GR1006941B (el) * 2009-06-01 2010-08-27 Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras), Πεπτιδικη συνθεση (peptide synthesis)
GR1007010B (el) 2009-10-08 2010-10-07 Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras), Ινσουλινοειδη πεπτιδια
GB201321489D0 (en) * 2013-12-05 2014-01-22 Chemical & Biopharmaceutical Lab Of Patras S A Biologically active insulin derivatives
US9982287B2 (en) * 2013-12-17 2018-05-29 Novo Nordisk A/S Enterokinase cleavable polypeptides

Also Published As

Publication number Publication date
AU2017322552A1 (en) 2019-03-28
CN110234339A (zh) 2019-09-13
EP3509625A1 (en) 2019-07-17
IL265182A (en) 2019-05-30
AU2017322552B2 (en) 2021-12-02
WO2018047062A1 (en) 2018-03-15
BR112019004314A2 (pt) 2019-05-28
CA3035850A1 (en) 2018-03-15
JP2019530473A (ja) 2019-10-24
US20190263881A1 (en) 2019-08-29
US11230585B2 (en) 2022-01-25

Similar Documents

Publication Publication Date Title
DK172456B1 (da) Lægemidler indeholdende insulinderivater til behandling af diabetes mellitus
US8445433B2 (en) Synthesis of glucagon-like peptide
KR102005385B1 (ko) 부위-특이적 모노-치환 페길화 엑센딘 유사체 및 그것의 제조방법
US20200317721A1 (en) A process for preparing a glucagon-like peptide
US11168114B2 (en) Process for the manufacture of degarelix and its intermediates
EP3580226A1 (en) Improved process for the preparation of a dodecapeptide
AU2003236080B2 (en) A method for producing a modified peptide
EP3888667B1 (en) Glucagon analog and methods of use thereof
AU2017248496B2 (en) Biologically active insulin derivatives
KR20190043609A (ko) 프로인슐린 유도체
CA2931439C (en) Biologically active insulin derivatives
WO2023118416A1 (en) Processes for synthesizing glucagon-like-peptide 2 (glp-2) analogues
JP2023541138A (ja) ペプチド及びタンパク質の誘導体化
CN111909255A (zh) 胰岛素衍生物及其制备方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190403

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200904

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220929

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20221212

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220929

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I